Importantly, inhibiting CD36 palmitoylation pharmacologically redirects CD36 to mitochondria, facilitating fatty acid transport for β-oxidation and consequently improving MASLD phenotypes [13]. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.